BioSpace News Archive

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release first quarter 2020 financial results after market close on Tuesday, May 5, 2020.

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial results after market close on Wednesday, May 6, 2020.

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that it has commenced an underwritten public offering of its common shares.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced that it will report financial results for the first quarter of 2020 after market close on Tuesday, May 5, 2020.

In a letter to the U.S. Department of HHS, the AANA has partnered with 24 national organizations to request Secretary Alex Azar support key provisions of the U.S. president’s executive order #13890, which provides a path to the permanent removal of burdensome supervision and licensure requirements for non-physician providers such as Certified Registered Nurse Anesthetists.

Gilead Sciences, Inc. (Nasdaq: GILD), Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.

Cutera, Inc. announced the closing of its previously announced underwritten public offering of 2,742,750 shares of its common stock at a public offering price of $10.50 per share, which includes the exercise in full of the underwriter’s option to purchase up to an additional 357,750 shares of its common stock at the same price per share to cover over-allotments.

Recently, the Food and Drug Administration (FDA) issued guidance to expand the availability and capability of non-invasive remote monitoring devices during the COVID-19 pandemic.

Emergent BioSolutions Inc. announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs.

IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company’s management will be participating in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference on April 23, 2020 from 12pm-5pm ET.